KGK Science, a North American contract research organization (CRO) specializing in nutraceuticals and dietary supplements, recently announced a growth investment led by Maxim Partners. This investment, finalized last month, aims to enhance KGK’s clinical trial capacity, promote decentralized and virtual trials, and expand its regulatory and commercial services, although financial details were not disclosed.
Founded in 1997 and based in London, Ontario, KGK has conducted over 400 clinical trials related to more than 40 health indications, contributing to over 150 peer-reviewed publications. The company advises consumer health firms on human clinical research, regulatory consulting, and claim substantiation on a global scale.
As the demand for scientifically validated health claims grows, particularly in the U.S. where the FDA mandates substantiation for certain dietary supplement claims, companies face increasing pressure to provide robust evidence of product efficacy. Guidance from the FDA and the FTC emphasizes the need for credible and relevant scientific evidence.
KGK’s investment will bolster its ability to assist nutraceutical brands in developing evidence-backed products, appealing to a market increasingly focused on clinical validation. Gregg Wilson, Managing Partner at Maxim Partners, highlighted KGK’s positioning to leverage ongoing industry trends, expressing enthusiasm about partnering with the company’s leadership.
Overall, the investment signifies the critical role of clinical evidence and regulatory expertise in helping companies differentiate themselves in the competitive nutraceutical sector, enabling KGK to support firms in developing proven consumer health products.
